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Abstract: Objectives: To assess whether cancer incidence, mainly from lymphohaematopoietic 
tumours and breast cancer, and mortality were increased in a cohort of Swedish sterilant 
workers exposed to low levels of ethylene oxide (EtO), updated with 16 more years of 
follow up.  Methods:  The  mortality  and  cancer  incidence  1972–2006  experienced  by  a 
cohort of 2,171 male and female workers employed for at least one year in two plants 
producing medical equipment sterilised with EtO were investigated. Individual cumulative 
exposure to EtO was assessed by occupational hygienists. Cause-specific standardized rate 
ratios were calculated using the regional general population as a comparison for mortality 
(SMR) and cancer incidence (SIR). Internal Poisson-regression analyses were performed 
for selected causes. Results: The median cumulative exposure to EtO was 0.13 ppm-years. 
The overall cancer incidence was close to unity (SIR 0.94, 95% CI 0.82–1.08). Eighteen 
cases of lymphohaematopoietic cancer were observed (SIR 1.25, 95% CI 0.74–1.98). A 
healthy worker effect was indicated from a significantly decreased overall mortality and 
mortality from cardiovascular diseases. Internal analyses found significantly increased rate 
ratios for breast cancer for the two upper quartiles of cumulative exposure as compared  
to the lowest 50% of the cohort (IRR 2.76, 95% CI 1.20–6.33 and IRR 3.55, 95% CI  
1.58–7.93). Conclusions: The findings from this updated study indicate limited or low risks 
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for human cancer due to occupational exposure from ethylene oxide at the low cumulative 
exposure levels in this cohort. However a positive exposure-response relation with breast 
cancer was observed though. 
Keywords: cohort study; leukaemia; breast cancer 
Abbreviations:  EtO:  Ethylene  oxide;  O:  Observed;  E:  Expected;  IRR:  Incidence  Rate 
ratio; SIR: Standardized Incidence Ratio; SMR: Standardized Mortality Ratio; 95% CI: 
95% confidence interval 
 
1. Introduction/Background 
Ethylene oxide (EtO) has been produced since the beginning of the 20th century, and the annual 
world production is around seven million tons [1]. In Sweden EtO is produced on a large scale and 
mainly used as an intermediate in the chemical industry. EtO is also used as a sterilising agent for 
medical equipment. This was the main source of occupational exposure to EtO in Sweden, though 
nowadays the levels of exposure must be considered to be low and the exposed workers probably to be 
few. In an international perspective EtO is still used in large scale and the exposure has been described 
in some recent studies [2-6]. 
The International Agency for Research on Cancer (IARC) has classified EtO as carcinogenic to 
humans [7]. The evaluation was based on a combination of mechanistic data and sufficient evidence 
for carcinogenicity in experimental animals, while the evidence for carcinogenicity in humans was 
assessed as limited. This evaluation was reaffirmed by IARC in 2009 [8]. 
Inhalation  of  ethylene  oxide  causes  cancer  at  multiple  sites  in  mice  (lung  tumours,  malignant 
lymphomas, uterine adenocarcinomas, and mammary carcinomas [9]), and in rats (leukaemia, brain 
tumours,  mesotheliomas  of  the  testis,  and  subcutaneous  fibromas  [10]).  A  large  epidemiologic  
study  of  18,000  employees  at  U.S.  sterilant  facilities  found  no  overall  increase  in  mortality  from 
lymphohaematopoietic  tumours  [11].  Associations  were,  however,  observed  between  cumulative 
exposure and mortality from non-Hodgkin’s lymphoma, multiple myeloma, and chronic lymphatic 
leukaemia  in  men.  Other  cohort  studies  have  reported  weak  and  non-significant  risks  for  these  
tumours [12,13]. A significantly increased breast cancer incidence among EtO exposed female sterilant 
workers has been reported [14], and an exposure—response relation between EtO exposure and breast 
cancer incidence was observed [15]. In contrast, some recent studies report low or no exposure related 
effects [16,17]. 
The  aim  of  the  present  study  was  to  assess  whether  cancer  incidence, especially from 
lymphohaematopoietic tumours and breast cancer, and mortality were increased at the low exposure 
levels experienced by the previously reported Swedish sterilant workers cohort [13], updated with 




2.1. Cohort and Plants 
The cohort comprised 2,171 workers (1,309 females and 862 males), employed for at least one year 
prior to 1986, at two plants producing medical equipment sterilised with EtO. Vital status in the cohort 
was determined on 31 December 2006 (Table 1). 









Living  1,003 (87.1)  871 (85.5)  1,874 (86.3) 
Dead  75 (6.5)  96 (9.4)  171 (7.9) 
Emigrated  74 (6.4)  52 (5.1)  126 (5.8) 
Total  1,152 (100)  1,019 (100)  2,171 (100) 
In plant A the sterilisation operations started in 1970 and ceased in 1994. The initial exposures in 
1970 could be as high as 40 ppm. Thereafter, the levels have continuously decreased, and since 1985 
only  sterilisers  have  had  eight  hour  time-weighted  exposures  exceeding  0.2  ppm.  Plant  B  started 
sterilising in 1964, and the process ceased in 2002. With initial peak exposure levels of 75 ppm in 
1964 plant B has also had a continuous decrease of exposure, and since 1985 only sterilisers and some 
store workers have had eight hour time-weighted exposures >0.2 ppm. 
2.2. Exposure Assessment 
A detailed exposure assessment including two plant specific job-exposure matrices was performed 
for exposures up to 1986 [18]. All workers that were still employed at the end of this earlier follow up 
were listed (n = 1,303), and the lists were distributed to the two companies. They added the work 
histories for these workers until 1994 (plant A) and 2002 (plant B) when the use of EtO ceased. 
Results from the yearly statutory hygienic measurements of EtO from 1986 and on, were retrieved. 
The exposures for the 1303 workers were assessed on the basis of the old job exposure matrices and 
the more recent measurements. The impact of the updated exposure on the cumulative EtO-exposure 
(Table 2) was low, as expected. An addition to the cumulative EtO-exposure was seen for 145 (11%) 
of the 1,303 workers, with changes to the cumulative EtO-exposure in the range of 0.01–3.7 ppm-
years. The greatest impact was on the 90th percentile which was changed from 1.17 to 1.29 ppm-years. Int. J. Environ. Res. Public Health 2011, 8         
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Table 2. Descriptive data for the Swedish sterilant workers cohort, as of 31 December 































Age (at end of follow up)  52.4 (51)  58.8 (58)  60.6 (60)  55.9 (55)  55.7 (55) 
Start of employment  1979 (1980)  1977 (1976)  1973 (1974)  1977 (1978)  1977 (1978) 
Total employment (years)  3.58 (3.33)  8.33 (8.51)  11.5 (10.9)  6.5 (6)  6.3 (5.7) 
Cumulative exposure to EtO  0.072 (0.07)  0.17 (0.17)  11.6 (0.39)  2.92 (0.13)   
Average exposure intensity (ppm)  0.0203 (0.02)  0.0206 (0.0202)  1.11 (0.1005 )  0.2877 (0.0202)   




































* Cumulative exposure could not be retrieved for 151 subjects due to lacking information on job titles. 
2.3. Information on Causes of Death and Tumours and Risk Estimates 
Information  on  cause  of  death  for  the  period  1972–2006,  coded  according  to  the  International 
Classification of Diseases (ICD), 8th revision, was provided by Statistics Sweden, and on malignant 
tumours for the period 1972–2006 (coded according to ICD, 7th revision) from the Swedish Cancer 
Registry. We obtained information on vital status and date of emigration as of December 31, 2006, from 
the Swedish population registry. One hundred and seventy one of the 2,171 workers were deceased, 126 
had emigrated and the rest were still alive and living in Sweden. None was lost to follow up. 
Expected  mortality  and  cancer  incidence  for  the  same  period  for  the  county  of  Scania  was 
calculated by means of the SYDCAP cohort program using cause-, calendar year, sex, and 5-yr age 
group-specific rates. These rates were calculated from incidence rates for specific causes-of-death and 
malignant tumours and population counts, obtained from Statistics Sweden and the Swedish Cancer 
Registry.  End of observation period, date  of  death,  or  date of emigration  was  used  as  individual 
endpoint  for mortality,  whichever  occurred  first.  For  cancer incidence,  date of second tumour 
diagnosis,  was  included as potential individual endpoint.  Altogether  the  cohort  contributed 
58,305 person-years  under  risk.  The  95%  confidence  intervals  (95%  CIs)  for  cause-specific 
standardised mortality and incidence ratios (SMRs and SIRs) were calculated by treating the observed 
number as a Poisson variable, or as a normal variable if the observed value was greater than 15. The 
term significant indicates that the 95% CI does not include 1.00. 
Expected mortality and cancer rates were calculated for the whole observation period 1972–2006, 
as well as for the earlier follow up period 1972–1990 which has been reported before [13], and the 
updated follow up period 1991–2006. Minor discrepancies in the expected numbers for the earlier 
follow up period may occur due to update of the software. Int. J. Environ. Res. Public Health 2011, 8         
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The extended follow up permitted us to use a 15 year induction latency period, rather than the 
10 years used in the previous update [13]. Internal analysis of cancer incidence (Incidence rate ratio, 
IRR)  between  exposure  categories  within  the  cohort  were  performed  by  means  of  Poisson 
regression [19] using EGRET software (Statistics and Epidemiology Research Corporation, Seattle). 
Analyses  were  adjusted  for  gender,  age  (0–49,  50–59,  60–69  &  ≥70)  and  calendar  period  
(1972/1976–1979, 1980–1989, 1990–1999 & 2000–2006) with no induction latency period. Internal 
analyses were focused on total cancer incidence and diagnoses with a priori observed associations with 
EtO exposure, i.e., breast cancer and lymphohaematopoietic cancers. 
3. Results 
3.1. Cancer Incidence 
The  SIR for overall  cancer  incidence  in the external comparisons  was  close  to  unity,  with 
203 observed  malignant  tumours,  compared  with  216  expected  (SIR  0.94,  95%  CI  0.82–1.08) 
(Table 3).  Eighteen  cases  of  lymphohaematopoietic  cancer  were  observed  (SIR  1.25,  
95% CI 0.74–1.98).  Out of those five cases were leukaemia (SIR 1.40, 95% CI 0.45–3.26), nine  
non-Hodgkin’s lymphoma (SIR 1.44, 95% CI 0.66–2.73), one Hodgkin’s lymphoma and two multiple 
myelomas.  Non-significantly  enhanced  rates  were  observed  for  cancer  in  the  oesophagus,  rectum, 
pancreas, cervix, urinary bladder, or brain. 
Table 3. Cancer incidence 1972 
*–2006 in EtO exposed workers employed for at least one year. 
   
No induction latency period  
(n = 2,171) (person-years = 58,220) 
≥15 years induction latency period  
(n = 2,046) (person-years = 27,415) 
Tumour site  ICD-7  O  E  SIR  95% CI  O  E  SIR  95% CI 
Oesophagus  150  3  1.63  1.84  0.38–5.38  3  1.40  2.14  0.44–6.26 
Stomach  151  3  3.72  0.81  0.17–2.36  3  2.73  1.10  0.23–3.21 
Colon  153  9  11.7  0.77  0.35–1.47  8  9.27  0.86  0.37–1.70 
Rectum  154  13  7.76  1.68  0.89–2.86  12  6.20  1.94  1.00–3.38 
Pancreas  157  6  3.79  1.58  0.58–3.45  4  2.94  1.36  0.37–3.48 
Lung  162  17  15.1  1.13  0.66–1.80  15  12.3  1.23  0.69–2.02 
Breast  170  41  50.9  0.81  0.58–1.09  33  38.54  0.86  0.59–1.20 
Cervix  171  8  6.38  1.25  0.54–2.47  4  3.10  1.29  0.35–3.30 
Prostate  177  17  15.3  1.11  0.65–1.78  16  14.24  1.12  0.64–1.82 
Urinary organs, including bladder  181  11  8.02  1.37  0.68–2.45  9  6.60  1.36  0.62–2.59 
Melanoma  190  8  12.7  0.63  0.27–1.25  5  8.11  0.62  0.20–1.44 
Nervous system, including brain  193  11  8.46  1.30  0.65–2.33  7  5.35  1.31  0.53–2.70 
Non Hodgkin’s lymphoma  200,202  9  6.25  1.44  0.66–2.73  7  4.68  1.50  0.50–3.08 
Hodgkin’s lymphoma  201  1  1.31  0.76  0.02–4.25  0  0.54  0.00  0.00–6.83 
Multiple myeloma  203  2  2.08  0.96  0.12–3.47  1  1.71  0.58  0.01–3.26 
Leukaemia  204–205  5  3.58  1.40  0.45–3,26  3  2.60  1.15  0.24–3.37 
Lymphohaematopoietic cancer  200–209  18  14.4  1.25  0.74–1.98  11  10.39  1.06  0.53–1.89 
All sites  140–209  203  216  0.94  0.82–1.08  159  162  0.98  0.84–1.15 
* The follow up period started 1976 for the workers from plant A. Int. J. Environ. Res. Public Health 2011, 8         
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Based  on  13  cases  an  unexpectedly  high  SIR  was  observed  for  rectal  cancer  (SIR  1.68;  
95%  CI  0.89–2.86),  with  12  of  the  cases  occurring  during  the  extended  follow up  1991–2006 
(SIR 1.92; 95% CI 0.99–3.35). 
Comparison of the risk patterns for the two follow up periods, 1972–1990 which has been reported 
before [13] and 1991–2006, showed a somewhat higher estimate for all sites for the latter (SIR 0.98, 
95% CI 0.83–1.14) than the earlier one (SIR 0.81, 95% CI 0.58–1.10; Table 4). However, during the 
latter observation period 12 new cases of lymphohaematopoietic tumours were observed, compared 
with 10.8 expected, giving a lower estimate (SIR 1.11, 95% CI 0.57–1.94) than for the earlier follow up 
(SIR 1.68, 95% CI 0.61–3.65). The same pattern was observed for leukaemia and multiple myeloma. 
When applying a 15 year induction latency period, the overall observed cancer incidence was similar, 
but the incidence of lymphohaematopoietic cancer was somewhat lowered.  
Table 4. Cancer incidence 1972 
*–2006 in EtO exposed workers employed for at least one 
year, divided by follow up period. No induction latency period was applied. 
   
Follow up period = 1972–1990 *  
(n = 2,171) (person-years = 26,674) 
Follow up period = 1991–2006  
(n = 2,077) (person-years = 31,546) 
Tumour site  ICD-7  O  E  SIR  95% CI  O  E  SIR  95% CI 
Oesophagus  150  0  0.12  0.00  0.00–30.7  3  1.41  2.13  0.44–6.22 
Stomach  151  0  0.95  0.00  0.00–3.88  3  2.78  1.08  0.22–3.15 
Colon  153  3  2.31  1.30  0.27–3.80  6  9.34  0.64  0.24–1.40 
Rectum  154  1  1.51  0.66  0.02–3.69  12  6.25  1.92  0.99–3.35 
Pancreas  157  2  0.86  2.33  0.28–8.40  4  2.93  1.37  0.37–3.50 
Lung  162  2  2.83  0.71  0.09–2.55  15  12.3  1.22  0.68–2.01 
Breast  170  5  11.5  0.43  0.14–1.01  36  39.4  0.91  0.64–1.27 
Cervix  171  6  2.98  2.01  0.74–4.38  2  3.40  0.59  0.07–2.12 
Prostate  177  2  1.00  2.00  0.24–7.22  15  14.3  1.05  0.59–1.73 
Urinary organs, including bladder  181  1  1.36  0.74  0.02–4.10  10  6.65  1.50  0.72–2.77 
Melanoma  190  2  4.02  0.50  0.06–1.80  6  8.65  0.69  0.25–1.51 
Nervous system, including brain  193  4  2.73  1.47  0.40–3.75  7  5.73  1.22  0.49–2.52 
Non Hodgkin’s lymphoma  200,202  2  1.37  1.46  0.18–5.27  7  4.89  1.43  0.58–2.95 
Hodgkin’s lymphoma  201  0  0.69  0.00  0.00–5.35  1  0.62  1.61  0.04–8.99 
Multiple myeloma  203  1  0.35  2.86  0.07–15.9  1  1.74  0.57  0.01–3.20 
Leukaemia  204–205  2  0.90  2.22  0.27–8.03  3  2.69  1.12  0.23–3,26 
Lymphohaematopoietic cancer  200–209  6  3.58  1.68  0.61–3.65  12  10.8  1.11  0.57–1.94 
All sites  140–209  41  50.3  0.81  0.58–1.10  162  166  0.98  0.83–1.14 
* The follow up period started 1976 for the workers from plant A. 
In  an  analysis  including  only  those  with  a  cumulative  EtO  exposure  above  the  median  value  
(0.13 ppm-years), and applying a 15 year induction latency period, the incidence ratio for all sites was 
slightly increased, but still non-significant (SIR 1.06, 95% CI 0.86–1.28). This was also the case for 
breast cancer (SIR 1.20, 95% CI 0.78–1.75), and cervical cancer (SIR 1.95, 95% CI 0.40–5.69; based 
on three cases), while the rates for lymphohaematopoietic cancer, were somewhat decreased. Further Int. J. Environ. Res. Public Health 2011, 8         
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restriction to cumulative exposure above the 75th percentile (0.22 ppm-years), increased the point 
estimate for breast cancer (SIR 1.41, 95% CI 0.82–2.26). 
Internal comparison by cumulative exposure (Table 5) revealed higher, but non-significant total 
cancer incidence in the two highest quartiles of cumulative exposure (IRR 1.37, 95% CI 0.95–1.97 and 
IRR 1.34, 95% CI 0.94–1.90 respectively). This was not observed for lymphohaematopoietic cancer. 
However, significantly increased rate ratios for breast cancer were observed for the two upper quartiles 
of cumulative exposure as compared to the lowest 50% of the cohort (IRR 2.76, 95% CI 1.20–6.33 and 
IRR 3.55, 95% CI 1.58–7.93). Internal analysis dichotomized by median of duration of employment 
(12–68 months vs. ≥69 months) showed similar results with IRR 1.37 (95% CI 1.01–1.86) for total 
cancer, and IRR 2.75 (95% CI 1.32–5.72) for breast cancer, while no such pattern was seen when 
dichotomizing by median of exposure intensity. 
Table 5.  External (SIR) and internal  (IRR)  comparison of cancer incidence between 
exposure categories within the cohort, calculated by Poisson regression using data stratified 
for gender, age and calendar period. ** 
Tumour site (ICD7)  Cases  Person-years  SIR  95% CI  IRR  95% CI 
All sites (140–209)             
0–0.13 ppm-years (n = 1,039)  67  25,707  0.87  0.68–1.11  1.00  - 
0.14–0.21 ppm-years (n = 486)  56  13,833  0.99  0.74–1.28  1.37  0.95–1.97 
≥0.22 ppm-years (n = 495)  70  14,509  1.00  0.78–1.26  1.34  0.94–1.90 
Breast cancer (170) *             
0–0.13 ppm-years (n = 615)  10  15,763  0.52  0.25–0.96  1.00  - 
0.14–0.21 ppm-years (n = 287)  14  8,245  1.06  0.58–1.78  2.76  1.20–6.33 
≥0.22 ppm-years (n = 295)  17  8,874  1.12  0.65–1.79  3.55  1.58–7.93 
Lymphohaematopoietic cancer (200–209)             
0–0.13 ppm-years (n = 1,039)  7  25,707  1.35  0.54–2.78  1.00  - 
0.14–0.21 ppm-years (n = 486)  5  13,833  1.32  0.43–3.09  1.17  0.36–3.78 
≥0.22 ppm-years (n = 495)  5  14,509  1.08  0.35–2.54  0.92  0.28–3.05 
* Only female workers were included in the calculation; ** One case of lymphohaematopoietic cancer and 
10 cases of all sites lost due to unknown cumulative exposure. 
3.2. Mortality 
The overall mortality was significantly decreased (SMR 0.84, 95% CI 0.72–0.98) (not shown in 
table). This was also the case for deaths from cardiovascular diseases (SMR 0.69, 95% CI 0.50–0.94), 
which comprise 25% of all deaths in the cohort. A slight but non-significant increase was found for 
deaths  from  all  malignancies (SMR  1.12,  95%  CI  0.89–1.40).  Based  on  10  cases  of  deaths  from 
pancreatic  cancer  an  enhanced  rate  was  seen  (SMR  2.05,  95%  CI  0.98–3.78).  Numerical  but  
non-significant increases of deaths from leukaemia, lymphoma and lung cancer were observed in the 
whole cohort, while slight but non-significant decreases were found for deaths from breast cancer, 
respiratory diseases and violent deaths. Point estimates (SMRs) for deaths from cancer of the pancreas 
and of the lung were higher among female workers, as compared to male workers. 
Applying a 15 year induction latency period enhanced the point estimate for the overall mortality, 
which no longer was significantly below unity (SMR 0.87, 95% CI 0.73–1.03). Thirty-five of the Int. J. Environ. Res. Public Health 2011, 8         
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43 deaths  from  cardiovascular  diseases  still  remained,  and  the  rate  was  still  significantly  lowered 
(SMR 0.69, 95% CI 0.48–0.96). The SMR for deaths from pancreatic cancer increased significantly 
(SMR  2.24,  95%  CI  1.02–4.25).  The  rates  for  deaths  from  lung  cancer  and  breast  cancer  were 
somewhat  increased,  while  the  estimates  for  deaths  from  leukaemia,  lymphoma  and  respiratory 
diseases, were lowered, all of them remaining non-significant. 
Restriction to workers with a cumulative exposure above the median value (0.13 ppm-years), and 
applying a 15 year induction latency period, still showed a low mortality from all causes (SMR 0.80, 
95% CI 0.63–0.99). A low risk was also seen for deaths from cardiovascular diseases (SMR 0.60,  
95% CI 0.37–0.91). Higher than expected rates were seen for deaths from breast cancer, pancreatic 
cancer  and  leukaemia,  while  slightly  decreased  point  estimates  for  deaths from  lung  cancer,  and 
respiratory diseases were observed, none of which were statistically significant. 
4. Discussion 
Adding 16 years of follow up to the cohort, the incident cancer cases increased almost six-fold, the 
number of deaths was five-fold higher, and the person years under risk more than doubled. However 
the cohort is still relatively young and the power for rare tumours such as lymphohaematopoietic ones 
is still not satisfactory. 
Significantly  decreased  overall  mortality  and  mortality  from  cardiovascular  diseases  indicated  
a  healthy  worker  effect.  Observed  overall  mortality  has  been  similarly  low  in  other  comparable  
cohorts  [11,16].  Internal  comparison  may  be  indicated  when  such  a  bias  occurs,  thus  Poisson 
regression analyses were performed for selected outcomes. 
The cohort as a whole had very low cumulative exposure to EtO, as compared to some recently 
studied cohorts [11,16]. Only about 10% of the cohort had a minimum of 1.0 ppm-years. On the other 
hand a vast majority of the cohort (95%) had individual data on cumulative exposure. The update of 
the EtO exposure in the cohort marginally changed the cumulative EtO exposure for a small part of the 
cohort (7%). 
The extended follow up permitted us to use an induction latency period of 15 years, as opposed to 
the 10 years used in the previous update of the cohort. The risk estimates are however similar (results 
not reported) whichever of the induction latency periods are chosen. 
Since the previous update of the cohort the incident cases of lymphohaematopoietic cancer has 
increased from 6 to 18 cases, and three new cases of leukaemia had been diagnosed. However, the 
point  estimates  for  both  groups  decreased  to  close  to  unity.  Thus,  this  new  follow up  (including 
internal comparisons) did not detect any excess risk from lymphatic and haematopoietic cancer at these 
low levels of exposure. 
Associations between EtO exposure and breast cancer incidence have been reported [14,15]. In our 
study the incidence of breast cancer, as well as the mortality from breast cancer, was increased when 
restricting the analysis to female workers with a cumulative EtO exposure above the median value of 
the cohort (0.13 ppm-years). An even higher incidence ratio for breast cancer was observed in a similar 
analysis restricted to workers in the upper quartile of EtO exposure (above 0.21 ppm-years). Internal 
direct comparison by cumulative EtO exposure showed higher incidence rate ratios for the two highest 
quartiles of exposure. Even though the two upper quartiles still include mainly very low exposures, Int. J. Environ. Res. Public Health 2011, 8         
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this supports the previous findings. However, the associations seemed to be driven more by duration  
of employment than intensity of exposure. Moreover, previous associations were  observed  for 
substantially  higher  exposures  [15]  (median  8.4  and  14  ppm-years  respectively  for  non-cases  
and cases). 
We did unfortunately not have information available on reproductive history, BMI or life style 
factors which are of importance for breast cancer risk [20]. Even though substantial confounding in 
occupational epidemiology is rare [21], and internal analyses are likely to reduce such systematic 
differences between exposure groups, it may still be present. Shift work occurred at both plants, but 
has overall been associated with only low to moderate excess of breast cancer risk [22].  
The  discrepancy  between  the  observed  10  deaths  from  pancreatic  cancer,  and  the  six  incident 
pancreatic diagnoses, might be due to the fact that in some cases no  pathological examination is 
available  and  the  tumour  may  thus  not  be  registered  as  a  primary  pancreatic  tumour  (personal 
communication from the Regional Tumour Registry). There might thus be an underestimate of the 
incident cases of pancreatic cancer. The elevated SIR found for rectal cancer was unexpected and has 
not been observed or reported from other occupational cohort studies of EtO. 
The findings from this study speaks for limited or low risks for human cancer due to occupational 
exposure to ethylene oxide in the low cumulative exposure window covered by this study. However, a 
positive exposure-response relation with breast cancer was observed in internal analyses, which give 
some support to similar findings from earlier studies.  
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